Inhibition of Receptor-Interacting Protein Kinase 1 in Chronic Plaque Psoriasis: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study

Inhibition of Receptor-Interacting Protein Kinase 1 in Chronic Plaque Psoriasis: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study

Abstract Introduction Receptor-interacting protein kinase 1 (RIPK1), a key mediator of inflammation through necroptosis and proinflammatory cytokine production, may play a role in the pathogenesis of immune-mediated inflammatory diseases such as chronic plaque psoriasis. An experimental medicine stu...

Full description

Bibliographic Details
Main Authors: Valerie J. Ludbrook, David C. Budd, Katie Thorn, Debra Tompson, Bartholomew J. Votta, Lucy Walker, Amy Lee, Xin Chen, Amanda Peppercorn, Wei Jing Loo
Format: Article
Language:English
Published: Adis, Springer Healthcare 2024-02-01
Series:Dermatology and Therapy
Subjects:
Psoriasis
RIP1K
Pharmacokinetics
Pharmacodynamics
PASI
Online Access:https://doi.org/10.1007/s13555-024-01097-0

Internet

https://doi.org/10.1007/s13555-024-01097-0

Similar Items